Zhengye Biotechnology Holding Ltd SEC filings ZYBT
Zhengye Biotechnology Holding Ltd has 61 filings in SEC EDGAR's recent list, going back to Aug 4, 2023. Its latest annual report, Form 20-F, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Aug 6, 2026.
| Form | Description | Filed | Period |
|---|---|---|---|
| NT 20-F | Notification of late filing | Apr 29, 2025 | Dec 31, 2024 |
| CERT | Filing | Jan 6, 2025 | — |
| EFFECT | Filing | Dec 20, 2024 | — |
| 8-A12B | For registration of certain classes | Dec 19, 2024 | — |
| EFFECT | Filing | Sep 30, 2024 | — |
| CORRESP | Letter to the SEC | Sep 26, 2024 | — |
| CORRESP | Letter to the SEC | Sep 26, 2024 | — |
| CORRESP | Letter to the SEC | Jun 14, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 4, 2024 | — |
| CORRESP | Letter to the SEC | Jan 9, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 27, 2023 | — |
| DRSLTR | Filing | Dec 14, 2023 | — |
| DRS/A | Filing | Dec 14, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 28, 2023 | — |
| DRSLTR | Filing | Nov 17, 2023 | — |
| DRS/A | Filing | Nov 17, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 17, 2023 | — |
| DRSLTR | Filing | Sep 28, 2023 | — |
| DRS/A | Filing | Sep 28, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 1, 2023 | — |
| DRS | Filing | Aug 4, 2023 | — |
Showing 21 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ZYBT (Nasdaq)
- Incorporated in
- China
- Headquarters
- Jilin
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1975641
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.